

Plant-Derived Alkaloids as Multifunctional Agents in Insulin Resistance, Obesity, and Metabolic Syndrome

Atukunda Derrick

Department of Pharmaceutical Microbiology and Biotechnology Kampala International University
Uganda

Email: derrick.atukunda@studwc.kiu.ac.ug

ABSTRACT

Metabolic syndrome, a cluster of interconnected metabolic disturbances including obesity, insulin resistance, dyslipidemia, and hypertension, represents a major global health challenge. Current therapeutic strategies often target individual components of the syndrome, yet their long-term efficacy is limited, and adverse effects remain a concern. Increasing attention has been directed toward natural bioactive compounds, particularly alkaloids from medicinal plants, as multifunctional agents capable of modulating multiple metabolic pathways simultaneously. Plant-derived alkaloids such as berberine, piperine, palmatine, and harmine have demonstrated significant potential in improving insulin sensitivity, regulating lipid metabolism, modulating gut microbiota, attenuating inflammation, and enhancing mitochondrial function. This review provides a comprehensive examination of plant alkaloids in the management of insulin resistance, obesity, and metabolic syndrome. The mechanistic insights, therapeutic prospects, and translational challenges of these compounds are explored, highlighting their promise as integrative interventions for complex metabolic disorders.

Keywords: plant-derived alkaloids, insulin resistance, obesity, metabolic syndrome, natural therapeutics

INTRODUCTION

The global burden of metabolic disorders has reached alarming levels, with obesity, insulin resistance, and metabolic syndrome emerging as central health challenges of the 21st century [1-3]. The World Health Organization estimates that more than one billion adults worldwide are overweight, with over 650 million classified as obese. These conditions are not isolated problems; rather, they converge into metabolic syndrome, a clinical constellation characterized by central adiposity, insulin resistance, hypertension, and dyslipidemia. Metabolic syndrome not only predisposes individuals to type 2 diabetes mellitus (T2DM) but also significantly elevates the risk of cardiovascular diseases, neurodegenerative disorders, and certain cancers [4-6]. The pathophysiological underpinnings of metabolic syndrome are complex, involving a dynamic interplay of genetic, environmental, and lifestyle factors that disrupt metabolic homeostasis [7-9].

At the core of these disturbances lies insulin resistance, defined as a reduced ability of peripheral tissues such as skeletal muscle, adipose tissue, and liver to respond to insulin's regulatory actions on glucose uptake and utilization. Insulin resistance contributes directly to hyperglycemia, hyperinsulinemia, and dyslipidemia, which further exacerbate adiposity and vascular complications [10]. Obesity, especially visceral fat accumulation, is closely linked to chronic low-grade inflammation, altered adipokine secretion, mitochondrial dysfunction, and lipid overload [11, 12]. Collectively, these factors form a vicious cycle that perpetuates metabolic dysfunction, underscoring the urgent need for novel therapeutic strategies capable of targeting multiple aspects of the syndrome simultaneously [13].

Conventional pharmacotherapies for obesity and insulin resistance include insulin sensitizers such as metformin, lipid-lowering agents like statins, and antihypertensive drugs. While these therapies provide partial symptomatic relief, they often address single components of metabolic syndrome rather than the multifaceted nature of the disorder. Moreover, long-term use of these drugs may be associated with adverse effects, compliance challenges, and limited sustainability [14]. Lifestyle interventions such as dietary modifications, exercise, and behavioral therapy remain cornerstones of management, yet their effectiveness is frequently undermined by poor adherence and environmental constraints. This therapeutic gap has stimulated growing

interest in natural product research, particularly the exploration of plant-derived bioactive compounds that may offer safe, multitargeted approaches to disease modification[15].

Among natural products, alkaloids constitute a structurally diverse and pharmacologically potent class of secondary metabolites with profound physiological effects. Defined by their basic nitrogen-containing heterocyclic structures, alkaloids have historically played vital roles in medicine, ranging from analgesics (morphine) and antimalarials (quinine) to anticancer agents (vincristine). In recent decades, increasing evidence has underscored the metabolic benefits of certain plant-derived alkaloids, many of which exert pleiotropic effects relevant to insulin resistance, obesity, and metabolic syndrome. Berberine, an isoquinoline alkaloid isolated from *Berberis* species, exemplifies such multifunctional action by activating AMP-activated protein kinase (AMPK), enhancing insulin signaling, improving lipid metabolism, and modulating gut microbiota composition[16]. Similarly, piperine from black pepper (*Piper nigrum*) improves glucose uptake and potentiates the bioavailability of other therapeutic compounds, while harmine and related alkaloids display notable effects on β -cell regeneration and glucose tolerance[17].

The mechanistic diversity of alkaloids arises from their ability to interact with molecular targets across multiple biological systems[16, 18, 19]. They regulate key signaling cascades such as AMPK, PI3K/Akt, and NF- κ B, modulate neurotransmitter activity, influence oxidative stress pathways, and restore mitochondrial efficiency. Importantly, several alkaloids exert dual actions on metabolic and inflammatory processes, which is crucial given that chronic inflammation is a hallmark of obesity-induced insulin resistance and metabolic syndrome. Their capacity to simultaneously improve energy homeostasis, reduce lipid accumulation, and attenuate systemic inflammation positions them as promising candidates for integrative metabolic therapies[20, 21].

Despite these encouraging findings, the therapeutic translation of plant alkaloids faces notable challenges, including variability in natural sources, limited bioavailability, potential toxicity at higher doses, and insufficient clinical validation. Nevertheless, advances in drug delivery systems, synthetic modifications, and nutraceutical formulations are helping to overcome these barriers, paving the way for more effective utilization of alkaloids in metabolic disease management[22–25]. This review aims to provide an updated and comprehensive examination of the role of plant-derived alkaloids as multifunctional agents in insulin resistance, obesity, and metabolic syndrome. By elucidating their mechanisms of action, therapeutic potential, and translational hurdles, this work highlights the promise of alkaloids as natural alternatives or complementary interventions to conventional therapies.

2. Alkaloids and Insulin Resistance

Insulin resistance is a central feature of metabolic syndrome and type 2 diabetes, characterized by impaired glucose uptake and utilization by peripheral tissues, including skeletal muscle, liver, and adipose tissue[26–28]. The inability of insulin to trigger proper glucose transport results in hyperglycemia and compensatory hyperinsulinemia, both of which exacerbate metabolic dysfunction and contribute to cardiovascular risk[29–31]. Plant-derived alkaloids have emerged as promising natural agents capable of targeting the molecular mechanisms underlying insulin resistance through multiple complementary pathways. Among them, berberine, an isoquinoline alkaloid derived from *Berberis* species, is extensively studied for its insulin-sensitizing properties[32, 33]. Berberine activates AMP-activated protein kinase (AMPK), a central metabolic regulator, thereby enhancing glucose uptake, suppressing hepatic gluconeogenesis, and stimulating fatty acid oxidation. By promoting translocation of glucose transporter type 4 (GLUT4) to the plasma membrane, berberine facilitates glucose entry into muscle and adipose tissues, bypassing defective insulin signaling[34].

Other alkaloids, such as piperine from black pepper (*Piper nigrum*), influence insulin sensitivity via modulation of the phosphoinositide 3-kinase (PI3K)/Akt pathway, a critical signaling cascade for insulin action. Piperine also improves the bioavailability of other therapeutic compounds, enhancing synergistic effects. Beyond these signaling effects, certain alkaloids protect pancreatic β -cells from oxidative stress-induced apoptosis, preserving insulin secretion[35, 36]. Harmine, an alkaloid from *Peganum harmala*, has been shown to promote β -cell proliferation and regeneration, offering a potential avenue for restoring endogenous insulin production.

Alkaloids also attenuate inflammation, a major contributor to insulin resistance. They inhibit nuclear factor- κ B (NF- κ B) signaling and reduce pro-inflammatory cytokines such as tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6), which are known to impair insulin receptor activity[37, 38]. Additionally, some alkaloids improve mitochondrial function, enhancing ATP production and reducing reactive oxygen species, which further strengthens insulin signaling. Collectively, the pleiotropic effects of alkaloids on glucose transport, insulin signaling, β -cell preservation, anti-inflammatory pathways, and mitochondrial efficiency position them as multifunctional agents capable of addressing multiple pathophysiological components of insulin resistance simultaneously[19, 39]. Continued exploration of these compounds, particularly in clinical settings, may provide valuable alternatives or adjuncts to conventional pharmacotherapy for metabolic disorders.

3. Alkaloids and Obesity

Obesity, particularly visceral adiposity, plays a central role in metabolic syndrome by promoting chronic inflammation, insulin resistance, dyslipidemia, and cardiovascular risk [8, 12, 32]. Plant-derived alkaloids exert significant anti-obesity effects through a combination of central and peripheral mechanisms. Berberine, for example, inhibits adipogenesis by downregulating key transcription factors such as peroxisome proliferator-activated receptor gamma (PPAR γ) and CCAAT/enhancer-binding proteins (C/EBPs), thereby limiting the differentiation of preadipocytes into mature adipocytes. This action reduces lipid accumulation in adipose tissue and lowers overall fat mass [7, 40]. In addition to inhibiting fat cell formation, alkaloids enhance lipolysis and fatty acid oxidation by activating AMPK and other metabolic regulators, thereby mobilizing stored triglycerides for energy utilization.

Certain alkaloids also influence appetite and energy intake. Nuciferine, isolated from lotus leaves, and piperine act on hypothalamic pathways to reduce food intake, modulate satiety hormones, and suppress excessive caloric consumption. By interacting with gut-brain signaling mechanisms, alkaloids contribute to long-term regulation of energy balance. Furthermore, many alkaloids modulate the gut microbiota, shifting microbial populations toward beneficial species associated with leanness, improved glucose tolerance, and reduced systemic inflammation [41, 42]. These microbial effects reinforce the metabolic benefits of alkaloids by enhancing nutrient absorption, regulating bile acid metabolism, and promoting short-chain fatty acid production.

Another critical anti-obesity mechanism of alkaloids involves thermogenesis. Harmine and evodiamine activate thermogenic pathways in brown and beige adipose tissue, increasing energy expenditure and promoting fat oxidation [43]. Additionally, alkaloids improve mitochondrial biogenesis and efficiency, enhancing overall metabolic rate. Through these multifaceted actions—including suppression of adipogenesis, promotion of lipolysis, appetite regulation, gut microbiota modulation, and thermogenic activation—plant-derived alkaloids emerge as holistic anti-obesity agents [44]. Their ability to target multiple pathogenic mechanisms simultaneously provides a distinct advantage over conventional weight-loss therapies, which often focus on a single pathway and may produce compensatory metabolic adaptations.

4. Alkaloids and Metabolic Syndrome

Metabolic syndrome is characterized by a complex interplay of obesity, insulin resistance, dyslipidemia, hypertension, and systemic inflammation, which collectively increase the risk of cardiovascular disease, type 2 diabetes, and related complications [4, 45, 46]. Plant-derived alkaloids offer an integrated approach to managing this syndrome due to their pleiotropic metabolic and anti-inflammatory actions. Berberine, for instance, improves lipid metabolism by reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides while increasing high-density lipoprotein cholesterol (HDL-C). This lipid-modulating effect is partly mediated by upregulation of LDL receptors and modulation of bile acid metabolism, resulting in enhanced cholesterol clearance [32, 44, 47, 48].

Alkaloids also exert beneficial effects on vascular function and blood pressure regulation. They improve endothelial function by enhancing nitric oxide bioavailability, reducing oxidative stress, and promoting vasodilation [49–54]. Piperine and harmine demonstrate anti-inflammatory effects by inhibiting NF- κ B signaling and decreasing circulating pro-inflammatory cytokines such as TNF- α and IL-6, mitigating the chronic low-grade inflammation associated with metabolic syndrome. Additionally, alkaloids enhance antioxidant defenses by stimulating superoxide dismutase, catalase, and glutathione peroxidase, thereby counteracting oxidative stress—a key contributor to vascular dysfunction and metabolic derangements.

These combined actions on glucose homeostasis, lipid profiles, inflammation, oxidative stress, and vascular health make alkaloids ideal candidates for comprehensive metabolic syndrome management [55–59]. Moreover, their multifunctional nature enables them to address multiple components of the syndrome simultaneously, reducing the need for polypharmacy and minimizing drug-drug interactions. By integrating metabolic, vascular, and inflammatory regulation, plant-derived alkaloids provide a holistic and systems-based therapeutic approach, offering the potential for both preventive and interventional strategies in metabolic syndrome management. Continued preclinical and clinical investigation is critical to confirm their efficacy, optimize dosing, and identify potential synergistic combinations with existing pharmacotherapies [60–67].

5. Challenges and Future Perspectives

Despite their promising therapeutic potential, plant-derived alkaloids face several challenges that limit their clinical translation. One major issue is poor bioavailability, often due to low intestinal absorption, rapid metabolism, and limited systemic circulation [68–74]. Berberine, for example, exhibits less than 1% oral bioavailability, which constrains its clinical efficacy. Innovative drug delivery systems including nanoparticles, liposomes, solid lipid carriers, and structural analogs are being developed to enhance absorption, prolong circulation, and target specific tissues [75–79]. Co-administration with absorption enhancers such as piperine also improves bioavailability and therapeutic effects.

Safety is another important consideration. While most alkaloids are generally well-tolerated at nutritional or therapeutic doses, higher concentrations may pose risks such as hepatotoxicity, neurotoxicity, or gastrointestinal disturbances [80–90]. Long-term toxicity studies and standardized dosing regimens are

therefore essential to ensure safe clinical application. Additionally, natural variability in alkaloid content due to differences in plant species, cultivation conditions, harvesting, and extraction methods complicates reproducibility and standardization of therapeutic formulations [90-100].

Future research should focus on rigorous clinical trials to validate the efficacy and safety of alkaloids in humans, as well as the development of combination therapies to exploit potential synergistic effects. Nutraceutical formulations and functional foods may provide a practical approach for preventive interventions [101-105]. Advances in metabolomics, pharmacogenomics, and personalized medicine could further enable tailored alkaloid-based therapies according to individual metabolic and genetic profiles. By addressing these challenges, plant-derived alkaloids could transition from experimental compounds to clinically relevant therapeutics for metabolic syndrome, insulin resistance, and obesity [106-110].

CONCLUSION

Plant-derived alkaloids represent a highly promising class of multifunctional agents capable of addressing the complex pathophysiology of insulin resistance, obesity, and metabolic syndrome. Their diverse mechanisms of action including enhancement of insulin signaling, preservation of pancreatic β -cell function, inhibition of adipogenesis, promotion of lipid metabolism, appetite regulation, thermogenic activation, anti-inflammatory effects, and antioxidant properties underscore their potential as integrated therapeutic agents. Unlike conventional pharmacological treatments, which often target single pathways, alkaloids offer a systems-based approach capable of modulating multiple metabolic processes simultaneously, providing holistic management of metabolic disorders. Despite encouraging preclinical and clinical evidence, translational barriers remain, including poor bioavailability, variability in natural sources, and potential toxicity at high doses. Advances in drug delivery systems, formulation technologies, and clinical validation are essential for overcoming these limitations. Furthermore, integrating alkaloids into combination therapies with conventional drugs or other bioactive compounds may enhance efficacy while minimizing adverse effects. Continued research into the molecular mechanisms, safety, and long-term outcomes of alkaloid-based interventions will be critical to establish their role in modern therapeutics. Overall, plant-derived alkaloids represent a unique convergence of natural product chemistry and modern pharmacology, offering promising opportunities to combat the global epidemic of metabolic disorders in a safe, effective, and multifaceted manner.

REFERENCES

1. Ahmed, S.K., Mohammed, R.A.: Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. *Metabolism Open*. 27, 100375 (2025). <https://doi.org/10.1016/j.metop.2025.100375>
2. Swarup, S., Ahmed, I., Grigorova, Y., Zeltser, R.: Metabolic Syndrome. In: StatPearls [Internet]. StatPearls Publishing (2024)
3. H, Z., Xd, Z., Md, S., Gyh, L., H, T., L, V., Vk, S., Cd, B., G, T., W, Y., O, V., Ck, O., Cs, M., Jd, R., Kyy, K., Na, J., N, P., Ag, R., A, A.-A., A, M., Yj, W., E, R.-Ú., O, O., Mc, K., F, L., N, M.-S., M, Z., A, L., H, A.M., Cj, T.-H., L, A., Sa, A.-B., Ai, S., Wk, C., Si, A., S, S., S, T., P, O., K, A., Ap, K., K, A., Mc, L.-L., Rj, O., O, S., Y, F., H, Z., Tn, A., Cs, K., A, P., O, T., A, A., Ga, M., Kc, S., Qf, C., Cra, L., Mh, Z.: Global burden of metabolic diseases, 1990-2021. *Metabolism: clinical and experimental*. 160, (2024). <https://doi.org/10.1016/j.metabol.2024.155999>
4. Adetunji, C.O., Michael, O.S., Rathee, S., Singh, K.R., Ajayi, O.O., Adetunji, J.B., Ojha, A., Singh, J., Singh, R.P.: Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight. *Materials Today Advances*. 13, 100198 (2022). <https://doi.org/10.1016/j.mtadv.2021.100198>
5. Bilog, N.C., Mekoulou Ndongo, J., Bika Lele, E.C., Guessogo, W.R., Assomo-Ndemba, P.B., Ahmadou, Etaga, N.B., Mbama Biloa, Y.J., Bindi, J.G.B.N., Temfemo, A., Mandengue, S.H., Guyot, J., Dupré, C., Barth, N., Bongue, B., Etoundi Ngoa, L.S., Ayina Ayina, C.N.: Prevalence of metabolic syndrome and components in rural, semi-urban and urban areas in the littoral region in Cameroon: impact of physical activity. *Journal of Health, Population and Nutrition*. 42, 95 (2023). <https://doi.org/10.1186/s41043-023-00415-0>
6. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? *Obesity Medicine*. 55, 100610 (2025). <https://doi.org/10.1016/j.obmed.2025.100610>
7. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR- γ expressions with reciprocal suppression of TNF- α gene in obesity. *J Cell Mol Med*. 28, e70086 (2024). <https://doi.org/10.1111/jcmm.70086>
8. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. *Natural Product Communications*. 20, 1934578X251344035 (2025). <https://doi.org/10.1177/1934578X251344035>

9. Uti, D.E., Ibiyam, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadium, S.K., Bawa, I., Alum, E.U., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: Buchholzia coriacea Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets In Silico. *Pharmaceutical Fronts.* 05, e141–e152 (2023). <https://doi.org/10.1055/s-0043-1772607>
10. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. *Obesity Medicine.* 100622 (2025). <https://doi.org/10.1016/j.obmed.2025.100622>
11. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. *Obesity Medicine.* 56, 100623 (2025). <https://doi.org/10.1016/j.obmed.2025.100623>
12. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A.: The Ketogenic Diet in Obesity Management: Friend or Foe? *Cell Biochem Biophys.* (2025). <https://doi.org/10.1007/s12013-025-01878-0>
13. Kong, Y., Yang, H., Nie, R., Zhang, X., Zuo, F., Zhang, H., Nian, X.: Obesity: pathophysiology and therapeutic interventions. *Mol Biomed.* 6, 25 (2025). <https://doi.org/10.1186/s43556-025-00264-9>
14. Rashid, R., Mir, S.A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., Bader, G.N.: Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. *Taiwanese Journal of Obstetrics and Gynecology.* 61, 40–50 (2022). <https://doi.org/10.1016/j.tjog.2021.11.009>
15. Espinosa-Salas, S., Gonzalez-Arias, M.: Behavior Modification for Lifestyle Improvement. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
16. Dey, P., Kundu, A., Kumar, A., Gupta, M., Lee, B.M., Bhakta, T., Dash, S., Kim, H.S.: Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids). *Recent Advances in Natural Products Analysis.* 505–567 (2020). <https://doi.org/10.1016/B978-0-12-816455-6.00015-9>
17. Stojanović-Radić, Z., Pejčić, M., Dimitrijević, M., Aleksić, A., V. Anil Kumar, N., Salehi, B., C. Cho, W., Sharifi-Rad, J.: Piperine-A Major Principle of Black Pepper: A Review of Its Bioactivity and Studies. *Applied Sciences.* 9, 4270 (2019). <https://doi.org/10.3390/app9204270>
18. Department of Basic Science, College of Dentistry, Mustansiriah University, Baghdad, Iraq, Mohammed, N.J., Al-Behadili, W.A.A., Department of Pharmacognosy and Medicinal Plants, College of Pharmacy, University of Misan, Iraq, Al-fahham, A.A., Faculty of Nursing, University of Kufa, Iraq: The Chemical Structure, Classification and Clinical Significance of Alkaloids. *IJHMR.* 03, (2024). <https://doi.org/10.58806/ijhmr.2024.v3i10n10>
19. Heinrich, M., Mah, J., Amirkia, V.: Alkaloids Used as Medicines: Structural Phytochemistry Meets Biodiversity—An Update and Forward Look. *Molecules.* 26, 1836 (2021). <https://doi.org/10.3390/molecules26071836>
20. Khan, A.Q., Rashid, K., AlAmodi, A.A., Agha, M.V., Akhtar, S., Hakeem, I., Raza, S.S., Uddin, S.: Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids. *Biomedicine & Pharmacotherapy.* 143, 112142 (2021). <https://doi.org/10.1016/j.biopha.2021.112142>
21. Krause, W.: Resistance to anti-tubulin agents: From vinca alkaloids to epothilones. *Cancer Drug Resist.* 2, 82–106 (2019). <https://doi.org/10.20517/cdr.2019.06>
22. Vaou, N., Voidarou, C. (Chrysa), Rozos, G., Saldari, C., Stavropoulou, E., Vrioni, G., Tsakris, A.: Unraveling Nature's Pharmacy: Transforming Medicinal Plants into Modern Therapeutic Agents. *Pharmaceutics.* 17, 754 (2025). <https://doi.org/10.3390/pharmaceutics17060754>
23. Ghosh, S., Solanki, R., Bhatia, D., Sankaranarayanan, S.: Nanomaterials for delivery of medicinal plant extracts and phytochemicals: Potential applications and future perspectives. *Plant Nano Biology.* 12, 100161 (2025). <https://doi.org/10.1016/j.plana.2025.100161>
24. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. *Phytomedicine Plus.* 5, 100828 (2025). <https://doi.org/10.1016/j.phyplu.2025.100828>
25. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. *Discover Nano.* 20, 70 (2025). <https://doi.org/10.1186/s11671-025-04248-0>
26. Abdelsalam, S.S., Korashy, H.M., Zeidan, A., Agouni, A.: The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance. *Biomolecules.* 9, 286 (2019). <https://doi.org/10.3390/biom9070286>
27. Aleksandrowicz, R., Strączkowski, M.: Link between insulin resistance and skeletal muscle extracellular matrix remodeling. *Endocr Connect.* 12, e230023 (2023). <https://doi.org/10.1530/EC-23-0023>

28. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health*. 22, 44 (2025). <https://doi.org/10.1186/s12982-025-00445-5>
29. Chandrasekaran, P., Weiskirchen, R.: Cellular and Molecular Mechanisms of Insulin Resistance. *Curr. Tissue Microenviron. Rep.* 5, 79–90 (2024). <https://doi.org/10.1007/s43152-024-00056-3>
30. Cao, X., Wang, N., Yang, M., Zhang, C.: Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease. *International Journal of Molecular Sciences*. 26, 6962 (2025). <https://doi.org/10.3390/ijms26146962>
31. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. *Diabetes & Vascular Disease Research*. 22, 14791641251334726 (2025). <https://doi.org/10.1177/14791641251334726>
32. Zieniuk, B., Pawełkowicz, M.: Berberine as a Bioactive Alkaloid: Multi-Omics Perspectives on Its Role in Obesity Management. *Metabolites*. 15, 467 (2025). <https://doi.org/10.3390/metabo15070467>
33. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. *Natural Product Communications*. 20, 1934578X251323393 (2025). <https://doi.org/10.1177/1934578X251323393>
34. Ren, G., Guo, J.-H., Qian, Y.-Z., Kong, W.-J., Jiang, J.-D.: Berberine Improves Glucose and Lipid Metabolism in HepG2 Cells Through AMPK α 1 Activation. *Front. Pharmacol.* 11, (2020). <https://doi.org/10.3389/fphar.2020.00647>
35. Liu, C., Yuan, Y., Zhou, J., Hu, R., Ji, L., Jiang, G.: Piperine ameliorates insulin resistance via inhibiting metabolic inflammation in monosodium glutamate-treated obese mice. *BMC Endocr Disord.* 20, 152 (2020). <https://doi.org/10.1186/s12902-020-00617-1>
36. Nguyen, M.H., Nguyen, T.Y.N., Le, T.H.N., Le, T.N.T., Chau, N.T.N., Le, T.M.H., Huy Nguyen, B.Q.: Medicinal plants as a potential resource for the discovery of novel structures towards cancer drug resistance treatment. *Heliyon*. 10, e39229 (2024). <https://doi.org/10.1016/j.heliyon.2024.e39229>
37. Kasimir, M., Wolbeck, A., Behrens, M., Humpf, H.-U.: Intestinal Metabolism of Selected Steroidal Glycoalkaloids in the Pig Cecum Model. *ACS Omega*. 8, 18266–18274 (2023). <https://doi.org/10.1021/acsomega.3c01990>
38. Ma, Z., Wang, S., Miao, W., Zhang, Z., Yu, L., Liu, S., Luo, Z., Liang, H., Yu, J., Huang, T., Li, M., Gao, J., Su, S., Li, Y., Zhou, L.: The Roles of Natural Alkaloids and Polyphenols in Lipid Metabolism: Therapeutic Implications and Potential Targets in Metabolic Diseases. *Curr Med Chem*. 30, 3649–3667 (2023). <https://doi.org/10.2174/0929867330666221107095646>
39. Sinden, S.L., Sanford, L.L., Webb, R.E.: Genetic and environmental control of potato glycoalkaloids. *American Potato Journal*. 61, 141–156 (1984). <https://doi.org/10.1007/BF02854035>
40. Jangra, A., Babu ,Basuvan, Divakar ,Selvaraj, Gowramma ,Byran, Rajan ,Saveri, Jangra ,Sonam, and Malakar, V.: An in-depth review of PPAR γ modulators as anti-diabetes therapeutics. *Drug Metabolism Reviews*. 0, 1–27. <https://doi.org/10.1080/03602532.2025.2508152>
41. Wang, Y., Yao, W., Li, B., Qian, S., Wei, B., Gong, S., Wang, J., Liu, M., Wei, M.: Nuciferine modulates the gut microbiota and prevents obesity in high-fat diet-fed rats. *Exp Mol Med*. 52, 1959–1975 (2020). <https://doi.org/10.1038/s12276-020-00534-2>
42. Alum, E.U., Uti, D.E., Ugwu, O.P.-C., Alum, B.N., Edeh, F.O., Ainebyoona, C.: Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. *Discov Oncol.* 16, 646 (2025). <https://doi.org/10.1007/s12672-025-02352-2>
43. Kou, G., Hu, Y., Jiang, Z., Li, Z., Li, P., Song, H., Chen, Q., Zhou, Z., Lyu, Q.: *Citrus aurantium* L. polymethoxyflavones promote thermogenesis of brown and white adipose tissue in high-fat diet induced C57BL/6J mice. *Journal of Functional Foods*. 67, 103860 (2020). <https://doi.org/10.1016/j.jff.2020.103860>
44. Kong, Y., Yang, H., Nie, R., Zhang, X., Zhang, H., Nian, X.: Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence. *Eur J Med Res*. 30, 477 (2025). <https://doi.org/10.1186/s40001-025-02738-6>
45. Collins, K.H., Herzog, W., MacDonald, G.Z., Reimer, R.A., Rios, J.L., Smith, I.C., Zernicke, R.F., Hart, D.A.: Obesity, Metabolic Syndrome, and Musculoskeletal Disease: Common Inflammatory Pathways Suggest a Central Role for Loss of Muscle Integrity. *Front. Physiol.* 9, (2018). <https://doi.org/10.3389/fphys.2018.00112>
46. Babaei, P., Hoseini, R.: Exercise training modulates adipokine dysregulations in metabolic syndrome. *Sports Med Health Sci*. 4, 18–28 (2022). <https://doi.org/10.1016/j.smhs.2022.01.001>
47. Babaei Khorzoughi, R., Namvarjah, F., Teimouri, M., Hosseini, H., Meshkani, R.: In-vitro Synergistic Effect of Metformin and Berberine on High Glucose-induced Lipogenesis. *Iran J Pharm Res*. 18, 1921–1930 (2019). <https://doi.org/10.22037/ijpr.2019.15085.12867>

48. Cai, Y., Yang, Q., Yu, Y., Yang, F., Bai, R., Fan, X.: Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review. *Front Pharmacol.* 14, 1283784 (2023). <https://doi.org/10.3389/fphar.2023.1283784>
49. Parvin, N., Aslam, M., Joo, S.W., Mandal, T.K.: Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications. *Molecules.* 30, 3177 (2025). <https://doi.org/10.3390/molecules30153177>
50. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. *Journal of Nanobiotechnology.* 23, 336 (2025). <https://doi.org/10.1186/s12951-025-03412-z>
51. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. *Int J Nanomedicine.* 20, 10101–10126 (2025). <https://doi.org/10.2147/IJN.S529250>
52. Akinboye, A.J., Kim, K., Choi, S., Yang, I., Lee, J.-G.: Alkaloids in food: a review of toxicity, analytical methods, occurrence and risk assessments. *Food Sci Biotechnol.* 32, 1133–1158 (2023). <https://doi.org/10.1007/s10068-023-01295-0>
53. Chen, R.J., Arora, R.D., Menezes, R.G.: *Vinca Alkaloid Toxicity*. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
54. Ezrari, S., Ben Khadda, Z., Boutagayout, A., Rehali, M., Jaadan, H., El Housni, Z., Khoulati, A., Saddari, A., Maleb, A.: Health risks and toxicity mechanisms of medicinal and aromatic plants (MAPs): A comprehensive review of adverse effects on organ systems, genotoxicity and reproductive toxicity. *Fitoterapia.* 184, 106630 (2025). <https://doi.org/10.1016/j.fitote.2025.106630>
55. Obeagu EI, Alum EU, Obeagu GU, Ugwu OP. Prostate Cancer: Review on Risk Factors. *Eurasian Experiment Journal of Public Health (EEJPH).* 2023;4(1):4-7.
56. Ugwu OP, Amasiorah VI. The effects of crude ethanol root extract and fractions of *sphenocentrum jollyanum* on the lipid profile of streptozotocin-induced diabetic wistar albino rats. *IDOSR Journal of Biology, Chemistry And Pharmacy.* 2020;5(1):36-46.
57. Igwenyi IO, Nchi PO, Okechukwu UP, Igwenyi IP, Obasi DC, Edwin N, Uraku AJ, Ze AC. Nutritional potential of *Azadirachta indica* seeds. *Indo American Journal of Pharmaceutical Sciences.* 2017 Feb 1;4(2):477-82.
58. Offor CE, Okaka AN, Ogbugo SO, Egbu CO, Ugwu PC. Effects of ethanol leaf extract of *Pterocarpus santalinoides* on haemoglobin, packed cell volume and platelets. *IOSR-JNHS* 2015; 4: 108. 2015;112:93.
59. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin: The gatekeeper of iron in malaria resistance. *Newport Int J Res Med Sci.* 2023;4(2):1–8. doi:10.59298/NIJRRMS/2023/10.1.1400.
60. Offor CE, Agidi JU, Egbu CO, Ezeani N, Okechukwu PCU. Vitamin and mineral contents of *Gongronema latifolium* leaves. *World J Med Sci.* 2015;12(2):189–91.
61. Ogbanshi ME, Agbafor KN, Ominyi CM, Okechukwu PCU, Nwali BU, Ali FU. Changes in reproductive functions of adult male rats administered water and salt samples from Okposi and Uburu Nigerian salt lakes. *Am Eurasian J Toxicol Sci.* 2015;7(2):55–62.
62. Okechukwu PCU, Offor CE, Ibiam UA, Ezugwu AL, Uraku AJ, Igwe CN, Okon MB. The effect of ethanol extract of *Jatropha curcas* on renal markers of chloroform intoxicated albino Wistar rats. *Eur J Biol Sci.* 2015;7(1):21–5. doi:10.5829/idosi.ejbs.2015.7.01.1106.
63. Offor CE, Aja PC, Ugwu O, Agbafo KN. The effects of ethanol leaf-extract of *Gmelina arborea* on total protein and albumin concentrations in albino rats. *Glob. J. Environ. Res.* 2015;9(1):1-4.
64. Alum E, Ugwu PC, Egba S, Uti D, Alum B. Extension, KP: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. *INOSR Scientific Research.* 11, 16–22 (2024) [Internet]. 2013
65. Onyeze RC, Udeh SM, Okwor JC, Ugwu OP. Isolation and characterization of bacteria that are associated with the production and spoilage of *ogi* (akamu). *International Journal of Pharma Medicine and Biological Sciences.* 2013;2(3):79-85.
66. Alum EU, Obeagu EI, Ugwu OP-C. Enhancing quality water, good sanitation, and proper hygiene is the panacea to diarrhea control and the attainment of some related sustainable development goals: A review. *Medicine (Baltimore).* 2024 Sep 20;103(38):e39578. doi:10.1097/MD.00000000000039578.
67. Alum EU, Uti DE, Obeagu EI, Ugwu OPC, Alum BN. Cancer's psychosocial aspects: impact on patient outcomes. *Elite J Med.* 2024;2(6):32–42.
68. Alum EU, Ugwu OP. Nutritional Strategies for Rheumatoid Arthritis: Exploring Pathways to Better Management. *INOSR Scientific Research.* 2023;10(1):18-26.

69. Alum EU, Mathias CD, Ugwu OP, Aja PM, Obeagu EI, Uti DE, Okon MB. Phytochemical composition of *Datura stramonium* ethanol leaf and seed extracts: A comparative study. *IAA Journal of Biological Sciences*. 2023;10(1):118-25.
70. Ugwu Okechukwu PC, Amasiorah VI. Review on Health Implications. Benefits and Biochemistry of Alcohol Intoxication, *INOSR Experimental Sciences*. 2020;6(1):62-74.
71. Ugwu O.P.C., Amasiorah VI. Review on Health Implications, Benefits and Biochemistry of Alcohol Intoxication. *INOSR Experimental Sciences*. 2020;6(1):62-74.
72. Okechukwu P, Ossai D, Tukur G, Eze O, Ekwueme OC. Bacteriuria and urinary schistosomiasis in primary school children in rural communities in Enugu State, Nigeria. *Pan African Medical Journal*. 2014;18:15.
73. Odo Christian E, Nwodo Okwesili FC, Joshua Parker E, Ugwu Okechukwu PC, Okonkwo CC. Acute Toxicity Investigation And Anti-Diarrhoeal Effect Of The Chloroform-Methanol Extract Of Seed Of *Persea Americana*. *Journal of Pharmacy Research*. 2013;6(2):331-5.
74. Alum EU, Uti DE, Ugwu OPC, Obeagu EI, Alum BN. Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. *Discov Onc*. 2025;16:646. doi:10.1007/s12672-025-02352-2.
75. Alum EU, Ugwu OPC, Egba SI, Uti DE, Alum BN. Climate variability and malaria transmission: unraveling the complex relationship. *INOSR Sci Res*. 2024;11(2):16-22. doi:10.59298/INOSRSR/2024/1.1.21622.
76. Ugwu CN, Okon MB, Ugwu OP. The Effects of Freezing on the Nutritional Composition of Fish. *INOSR Experimental Sciences*. 2024;13(1):61-5.
77. Alum EU, Ugwu OP, Obeagu EI, Orji OU, Edwin N, Okon MB. Religious Leaders as Advocates for Promoting Exclusive Breastfeeding in East Africa. *International Journal of Innovative and Applied Research*. 2023;11(12):10-5.
78. Obeagu EI, Obeagu GU, Alum EU, Ugwu OP. Comprehensive Review of Antiretroviral Therapy Effects on Red Blood Cells in HIV Patients. *INOSR Experimental Sciences*. 2023;12(3):63-72.
79. Onyeze RC, Onah GT, Onwukwe CL, Ugwu OPC. Comparative effects of neem and lemongrass leaf extracts on *Salmonella* spp. *World J Pharm Res*. 2013;2(4):1177-1185.
80. Obeagu EI, Obeagu GU, Alum EU, Ugwu OP. Understanding the Impact of HIV-Associated Bone Marrow Alterations on Erythropoiesis. *INOSR Scientific Research*. 2023;10(1):1-1.
81. Ugwu Okechukwu PC, Amasiorah VI. The In vitro Antioxidant Potentials of the Crude Ethanol Root Extract and Fractions of *Sphenocentrum jollyanum*. *INOSR Applied Sciences* 6 (1). 2020:125-33.
82. Ugwu Okechukwu PC, Onyeneke EC, Igwenyi IO, Aja PM, Ugwuoke KC, Okon Michael B, Onyeneke SC. The Effects of Crude Ethanol Root Extract and Fractions of *Sphenocentrum jollyanum* on Liver and Kidney Function Parameters of Streptozotocin Induced Diabetic Wistar Aja PM, Udeh SM, Opajobi AO, Uzuegbu UE, Alum EU, Edwin N, Okechukwu UP. HEPATO-PROTECTIVE EFFECT OF AQUEOUS LEAF-EXTRACT OF *TALINUM TRIANGULARE* IN MONOSODIUM GLUTAMATE (MSG) INDUCED HEPATIC DAMAGE IN ALBINO RATS. *Indo American Journal of Pharmaceutical Sciences*. 2017 Feb 1;4(2):464-70. Albino Rats. *IAA Journal of Scientific Research*. 2018;4(1):75-90.
83. Offor C, Chukwu B, Igwenyi I, Ugwu OP, Aja P. Effect of Ethanol Leaf-Extract of *Annona muricata* on Serum Total Protein and Albumin Concentrations in Albino Rats. *Academic Journal of Oral and Dental Medicine*. 2015;2(1):5-7.
84. Chukwuezi Fabian O, Ugwu Okechukwu PC. Distribution of *Mycobacterium bacilli* in Onitsha Metropolis and its Relationship with HIV Infection. *Pharmanest An International Journal of Advances in Pharmaceutical Sciences*. 2013;4(5):902-6.
85. Uti DE, Alum EU, Atangwho IJ, Obeagu EI, Ugwu OPC. Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. *J Nanobiotechnol*. 2025;23:336. doi:10.1186/s12951-025-03412-z.
86. Alum EU, Ugwu OPC. Artificial intelligence in personalized medicine: transforming diagnosis and treatment. *Discov Appl Sci*. 2025;7:193. doi:10.1007/s42452-025-06625-x.
87. Onyeze RC, Udeh SMC, Ani LC, Ugwu OPC. Microbiology of honey collected from three different locations in Enugu State, Nigeria. *World J Pharm Res*. 2013;2(4):1086-1095.
88. Enechi OC, Ibechem Augustine C, Ugwu Okechukwu PC. Distribution of Iodine and some goitrogens in two selected water bodies (Kalawa and Adaoka Rivers) in Enugu State, Nigeria. *Exp. Int. J. Sci. Technol*. 2013;12(1):748-61.
89. Alum EU, Obeagu EI, Ugwu OPC, Alum BN, Arinze ED, Ukaidi CUA. Exploring the differential impacts of intermittent fasting on men and women. *Elite J Health Sci*. 2024;2(5):37-44.
90. Edwin N, Obasi DC, Offor CE, Obasi JN, Ugwu OPC, Aja PM, Ogbanshi ME, Uraku AJ, Alum EU, Ali FU. Impact of soil physicochemical properties on mineral composition of cassava samples from Ikwo LGA of Ebonyi State, Nigeria. *J Chem Soc Niger*. 2022;47(6). doi:10.46602/jcsn.v47i6.821.

91. Ikezu UJM, Ajiwe VIE, Iloh EO, Okechukwu PCU. Phytochemical and atomic absorption spectroscopic analysis of root, stem and leaf extracts of *Acanthus montanus*. *Middle East J Sci Res.* 2014;21(6):875–878.
92. Udeozo IP, Akpaba ES, Ugwu OPC, Okoye NH, Umedum NL. Qualitative alkaloidal analyses of some selected Nigerian medicinal plants used in herbal treatment of diseases. *Int J Life Sci Biotechnol Pharm Res.* 2013;2(3):300–305.
93. Onyeze RC, Udeh SMC, Ilo PC, Ugwu OPC. Antibacterial evaluation of *Moringa oleifera* leaf extract on selected bacterial pathogens (*Escherichia coli*, *Staphylococcus aureus* and *Pseudomonas aeruginosa*). *World J Pharm Res.* 2013;2(4):1065–1077.
94. Alum EU, Obasi DC, Abba JN, Aniokete UC, Okoroh PN, Ugwu OPC, Uti DE. Endogenous plant signals and human health: molecular mechanisms, ecological functions, and therapeutic prospects. *Biochem Biophys Rep.* 2025;43:102114. doi:10.1016/j.bbrep.2025.102114.
95. Mezieobi KC, Alum EU, Ugwu OPC, Uti DE, Alum BN, Egba SI, Ewah CM. Economic burden of malaria on developing countries: a mini review. *Parasite Epidemiol Control.* 2025;30:e00435. doi:10.1016/j.parepi.2025.e00435.
96. Alum EU, Nwuruku OA, Ugwu OPC, Uti DE, Alum BN, Edwin N. Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. *Phytomed Plus.* 2025;5(3):100828. doi:10.1016/j.phyplu.2025.100828.
97. Nyamboga TO, Ugwu OPC, Ugwu JN, Alum EU, Eze VHU, Ugwu CN, Ejemot-Nwadiaro RI. Biotechnological innovations in soil health management: a systematic review of integrating microbiome engineering, bioinformatics, and sustainable practices. *Cogent Food Agric.* 2025;11(1):2519811. doi:10.1080/23311932.2025.2519811.
98. Madu CV, Alum EU, Aloh HE, Ugwu OPC, Obeagu EI, Uti DE, Egba SI, Ukaidi CUA, Alum NB. The price of progress: assessing the financial costs of HIV/AIDS management in East Africa. *Medicine (Baltimore).* 2025;104(18):e42300. doi:10.1097/MD.00000000000042300.
99. Ugwu OPC, Anyaegbunam CN, Uzochukwu MN, Onohuean H. Harnessing plant metabolic pathways for innovative diabetes management: unlocking the therapeutic potential of medicinal plants. *Plant Signal Behav.* 2025;20(1):2486076. doi:10.1080/15592324.2025.2486076.
100. Ogbodo JO, Egba SI, Ikechukwu GC, Paul PC, Mba JO, Ugwu OPC, Ezike TC. Volatile organic compound–drug receptor interactions: a potential tool for drug design in the search for remedies for increasing toxic occupational exposure. *Processes.* 2025;13(1):154. doi:10.3390/pr13010154.
101. Nwite MO, Agwu SC, Afiukwa CA, Ugwu OPC. Comprehensive phenotypic assessment of rice diseases in cultivated farms within Okpuitumo Community, Ikwo Local Government Area, Ebonyi State: implications for sustainable rice crop management. *Newport Int J Biol Appl Sci.* 2023;4(1):26–31. doi:10.59298/NIJBAS/2023/1.4.11111.
102. Uraku AJ, Okechukwu PCU, Nzubechukwu E. Preliminary phytochemical screening of *Spilanthes uliginosa*, *Ocimum basilicum*, *Hyptis spicigera* and *Cymbopogon citratus* leaf extracts and haematological changes of mice infected with malaria parasite. *Am Eurasian J Sci Res.* 2015;10(1):12–17.
103. Enechi OC, Ogochukwu BO, Okechukwu PCU. Effect of fermentation on biochemical properties of maize (*Zea mays* L.). *World Appl Sci J.* 2014;31(5):724–729.
104. Onyeze RC, Onah GT, Nwadi NO, Ugwu OPC. Bacteriological examination of abattoir with reference to *Escherichia coli* and *Staphylococcus* species. *World J Pharm Res.* 2013;2(4):1154–1163.
105. Ogugua VN, Anaduaka EG, Chijioke C, Egba SI, Ugwu OPC. Effects of storage on auto-oxidation levels of selected alcoholic and non-alcoholic beverages in Nsukka town, Enugu State of Nigeria. *World J Pharm Res.* 2013;2(4):758–764.
106. Ogugua VN, Anaduaka EG, Chijioke C, Egba SI, Ugwu OPC. Effects of storage on auto-oxidation levels of selected alcoholic and non-alcoholic beverages in Nsukka town, Enugu State of Nigeria. *World J Pharm Res.* 2013;2(4):758–764.
107. Omeh YS, Ijioma VU, Ugwu OPC, Enechi OC. Characterisation and fatty acid profile of *Cucurbita pepo* seed oil. *World J Pharm Pharm Sci.* 2013;2(3):825–832.
108. Omeh YS, Ugwu OPC, Enechi OC. The effect of feeding *Mucuna* oil on the lipid profile and creatine kinase enzyme of albino rats. *World J Pharm Pharm Sci.* 2013;2(3):802–813.
109. Enechi OC, Obiora EN, Okechukwu PU. Chromatographic Identification and the Effect of the Alkaloidal Extract of *Bucchozia coriacea* Seeds on the Body Weights and Relative Liver Weights of Mice. *Advances in Biological Research.* 2013;7(5):188–93.
110. Mezieobi KC, Alum EU, Ugwu OPC, Uti DE, Alum BN, Egba SI, Ewah CM. Economic burden of malaria on developing countries: a mini review. *Parasite Epidemiol Control.* 2025;30:e00435. doi:10.1016/j.parepi.2025.e00435.

CITE AS: Atukunda Derrick (2025). Plant-Derived Alkaloids as Multifunctional Agents in Insulin Resistance, Obesity, and Metabolic Syndrome. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 11(2): 99-108. <https://doi.org/10.59298/IDOSR/JES/112.99108>